Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong – Clinical outcomes, barriers to vaccination, and urgency for reform

Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong – Clinical outcomes, barriers to vaccination, and urgency for reform

Introduction: Hong Kong has had a low incidence of COVID-19 vaccine related anaphylaxis, partly due to its Vaccine Allergy Safety (VAS) guidelines for screening those at higher risk of COVID-19 vaccine-associated allergic reactions. We characterize the initial experience of the VAS clinics, as well...

Full description

Bibliographic Details
Main Authors: Valerie Chiang, Sabrina Wing Shan Mok, MA, RD, June King Chi Chan, MSc, RD, Wai Yan Leung, Carmen Tze Kwan Ho, MBBS (HK), FRCP (Edin, London), FHKCP, FHKAM (Medicine), Elaine Y.L. Au, MBBS, FHKAM (Medicine), FRCPA, FHKAM (Pathology), D (ABMLI), Chak Sing Lau, MBChB, MD (Hons), FRCP (Edin, Glasg, Lond), FHKCP, FHKAM (Medicine), Tak Hong Lee, MBBChir (Cantab), MD (Cantab), ScD (Cantab), MRCP (UK), MRCPath, FRCP (Lond), FRCPath, FHKCP, Philip Hei Li, MB BS (HK), M Res (Med) (HK), PDipID (HK), MRCP (UK), FHKCP, FHKAM (Medicine)
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:World Allergy Organization Journal
Subjects:
COVID-19
Vaccine
Allergy
Hypersensitivity
Safety
Hong Kong
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455121001162

Internet

http://www.sciencedirect.com/science/article/pii/S1939455121001162

Similar Items